Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF

Bone Marrow Transplantation volume 35, pages 449–454 (2005)Cite this article

Summary:

The ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) regimen has been shown to be effective as an active salvage therapy for lymphoma. Mobilizing stem cells following ESHAP should decrease time to transplantation by making separate mobilizing chemotherapy (MC) unnecessary, while controlling a patient's lymphoma. We therefore assessed the mobilization potential of ESHAP plus G-CSF in 26 patients (ESHAP group) with non-Hodgkin's lymphoma (NHL) and compared these results with those of 24 patients with NHL who received high-dose (4 g/m2l) cyclophosphamide (HDCY) as MC (HDCY group). The age, sex, and radiotherapy to the axial skeleton were well matched between groups, but the number of patients with poor mobilization predictors was higher in the ESHAP group. Significantly higher numbers of CD34+ cells (× 106/kg) (17.1±18.8 vs 5.8±5.0, P=0.03) and apheresis day 1 CD34+ cells (× 106/kg) (5.5±6.6 vs 1.7±2.0, P=0.014) were collected from the ESHAP group than from the HDCY group, and the number of patients who achieved an optimal CD34+ cell target of 5 × 106/kg was higher in the ESHAP group (81 vs 50%, P=0.022). Log-rank test revealed that time to target peripheral blood progenitor cell collection (⩾5 × 106/kg) was shorter in the ESHAP group (P=0.007). These results indicate that ESHAP plus G-CSF is an excellent mobilization regimen in patients with relapsed and poor-risk aggressive NHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413.

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  3. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  Google Scholar 

  4. Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–697.

    CAS  Google Scholar 

  5. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176.

    Article  CAS  Google Scholar 

  6. Rodriguez-Monge EJ, Cabanillas F . Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Center experience. Hematol Oncol Clin N Am 1997; 11: 937–947.

    Article  CAS  Google Scholar 

  7. Petit J, Boque C, Cancelas JA et al. Feasibility of ESHAP+G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leukemia Lymphoma 1999; 34: 119–127.

    Article  CAS  Google Scholar 

  8. Berdeja JG, Ambinder RF, Jones RJ et al. Stem cell mobilization with G-CSF following standard ESHAP chemotherapy in patients with lymphoma. Blood 2001; 98: 456 (abstr. 754).

    Google Scholar 

  9. Watts MJ, Ings SJ, Leverett D et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282.

    Article  CAS  Google Scholar 

  10. Lee JL, Kim SB, Lee GW et al. The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Yonsei Med J 2003; 44: 800–810.

    Article  CAS  Google Scholar 

  11. Lee JL, Kim SB, Lee GW et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003; 18: 27–35.

    Article  Google Scholar 

  12. Park KU, Kim SH, Suh C et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67: 42–47.

    Article  CAS  Google Scholar 

  13. Suh C, Kim S, Kim S-H et al. Initiation of peripheral blood stem cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE-9000. Transfusion 2004; 44: 1762–1768.

    Article  Google Scholar 

  14. Lee JL, Kim SB, Lee GW et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apheresis Sci 2003; 29: 29–37.

    Article  Google Scholar 

  15. To LB, Haylock DN, Simmons PJ, Juttner CA . The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–2258.

    CAS  Google Scholar 

  16. Pavone V, Gaudio F, Guarini A et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.

    Article  CAS  Google Scholar 

  17. Olivieri A, Offidani M, Ciniero L et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16: 85–93.

    CAS  Google Scholar 

  18. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785.

    Article  CAS  Google Scholar 

  19. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.

    Article  CAS  Google Scholar 

  20. Watts MJ, Sullivan AM, Ings SJ et al. Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 1997; 20: 157–162.

    Article  CAS  Google Scholar 

  21. Le Gouill S, Moreau P, Morineau N et al. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. Haematologica 2002; 87: 333–334.

    Google Scholar 

  22. Allan DS, Keeney M, Howson-Jan K et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967–972.

    Article  CAS  Google Scholar 

  23. Dreger P, Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with ‘Dexa-BEAM’ and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950–957.

    Article  CAS  Google Scholar 

  24. McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228–233.

    Article  CAS  Google Scholar 

  25. Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 873–878.

    Article  CAS  Google Scholar 

  26. Weaver CH, Zhen B, Buckner CD . Treatment of patients with malignant lymphoma with mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant 1998; 21: 1169–1170.

    Article  CAS  Google Scholar 

  27. Zinzani PL, Barbieri E, Visani G et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 1994; 79: 508–512.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    J-L Lee, S Kim, S W Kim, E-K Kim, S-B Kim, Y-K Kang, J Lee, M W Kim, S-H Kim & C Suh

  2. Department of Diagnostic Laboratory Medicine, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    C J Park & H-S Chi

  3. Department of Pathology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    J Huh

  4. Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea

    J-L Lee

Authors
  1. J-L Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S-B Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-K Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C J Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H-S Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S-H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Suh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, JL., Kim, S., Kim, S. et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 35, 449–454 (2005). https://doi.org/10.1038/sj.bmt.1704798

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704798

Keywords

This article is cited by

Search

Advanced search

Quick links